Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1128-1147, May 2026.Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley +1 more source
Delayed urticaria during treatment with anti‐CGRP monoclonal antibodies in migraine
Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1193-1199, May 2026.Abstract Objective To characterize clinical presentation and management of urticaria associated with calcitonin gene‐related peptide (CGRP) ‐targeting monoclonal antibodies (mAbs) for migraine prophylaxis. Background CGRP‐targeting mAbs are effective in migraine prophylaxis, but have been associated with hypersensitivity reactions, including urticaria.
Christoph T. Berger +5 more
wiley +1 more source
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. [PDF]
, 2019 OBJECTIVE: To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODS:
Cheng, Sunfa +10 more
core +1 more source
Triggers, Protectors, and Predictors in Episodic Migraine. [PDF]
, 2018 PURPOSE OF REVIEW: A wide variety of triggers prompt attacks in episodic migraine. Although experimental triggers such as glyceryl trinitrate reliably produce migraine, natural triggers are much less predictable and vary in importance between individuals.
Marmura, Michael J.
core +1 more source
Migraine: Diagnosis, treatment and understanding c1960-2010 [PDF]
, 2014 seminar transcriptThere are around eight million migraine sufferers in the UK today. This Witness Seminar looked at the last 50 years of research into the diagnosis and treatment of the condition and the changing attitudes of the medical profession ...
Overy, C, Tansey, EM
core
DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment. [PDF]
, 2019 BackgroundThe commercial formulation of sumatriptan nasal spray is an effective option for migraine patients requiring or preferring a non-oral route of drug administration, but its utility is limited by poor absorption and tolerability issues. DFN-02, a
Brand-Schieber, Elimor +3 more
core
Preventing and treating medication overuse headache
PAIN Reports, 2017 Karl B. Alstadhaug, MD, PhD +2 more
doaj +1 more source
GBD 2015: migraine is the third cause of disability in under 50s [PDF]
, 2016 Steiner, TJ, Stovner, LJ, Vos, T
core +1 more source
DNA methylation signatures of treatment response in medication-overuse headache. [PDF]
J Headache PainKwiatkowska KM +16 more
europepmc +1 more source
Response to Mehuys et al. 'Self-medication of regular headache: a community pharmacy-based survey'
, 2012 Boussery, Koen +2 more
core +1 more source